EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited‐stage small‐cell lung cancer: A retrospective, multi‐center, real‐world study

Zichen Zhao, Hao Rong, Mengxia Li, Yong Xu, Long Tian, Xiaoming Qiu, Hu Liao, Yalun Li, Ke Wang, Xiaojun Tang, Panwen Tian iD, Daxing Zhu und 2 weitere

International Journal of Cancer · 15.02.2026 · 158 (4) · 1008-1020

DOI: 10.1002/ijc.70153 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 13.09.2025. Verfasst von Zichen Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Small Cell Lung Carcinoma, Lung Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University, The Key R&D Projects of the Health Commission of Sichuan Province, Chinese Academy of Medical Sciences Clinical and Translation Medical Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical value of neoadjuvant immunochemotherapy in limited‐stage small‐cell lung cancer (LS‐SCLC) remains poorly defined, with limited comparative data available against concurrent chemoradiotherapy (CCRT). This retrospective multicenter study evaluated the efficacy and safety of neoadjuvant immunochemotherapy, chemotherapy, and CCRT in treatment‐naive patients with potentially resectable SCLC. A total of 139 patients treated between February 2019 and December 2023 were included: 55 received CCRT, and 84 underwent neoadjuvant therapy followed by surgery (28 immunochemotherapy, 56 chemotherapy). Complete (R0) resection was achieved in all surgical cases. The pathological complete response (pCR) rate was significantly higher in the immunochemotherapy group than in the chemotherapy group (35.7% vs. 7.1%, p < .05), as was the major pathological response (MPR) rate (53.6% vs. 12.5%, p < .05). Adverse events were acceptable in the three groups. After propensity score matching (PSM), 24 patients from each group were included for survival analysis. Although median progression‐free survival (PFS) and overall survival (OS) were not reached in the immunochemotherapy group, Kaplan–Meier analysis showed significantly prolonged PFS and OS compared with both chemotherapy and CCRT. These results suggest that neoadjuvant immunochemotherapy is a safe and effective treatment strategy for LS‐SCLC and merits further investigation in prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapySmall Cell Lung CarcinomaLung NeoplasmsChemoradiotherapyImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeAdultNeoplasm Staging

Stichwörter der Autor:innen

limited‐stageneoadjuvant chemotherapyneoadjuvant immunochemotherapysmall‐cell lung cancer

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Oncology, Daping Hospital, Army Medical University, Chongqing, China.
  • Division of Thoracic Oncology, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Panwen Tian, Yan Zhang

Förderung

  • The 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University
  • The Key R&D Projects of the Health Commission of Sichuan Province
  • Chinese Academy of Medical Sciences Clinical and Translation Medical Program

Zitieren

APA

Zhao, Z., Rong, H., Li, M., Xu, Y., Tian, L., Qiu, X., Liao, H., Li, Y., Wang, K., Tang, X., Tian, P., Zhu, D., Zhou, Q., & Zhang, Y. (2026). Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited‐stage small‐cell lung cancer: A retrospective, multi‐center, real‐world study. International Journal of Cancer, 158(4), 1008-1020. https://doi.org/10.1002/ijc.70153

Vancouver

Zhao Z, Rong H, Li M, Xu Y, Tian L, Qiu X, et al. Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited‐stage small‐cell lung cancer: A retrospective, multi‐center, real‐world study. International Journal of Cancer. 2026;158(4):1008-1020. doi:10.1002/ijc.70153

BibTeX
@article{Zhao2026,
  author = {Zhao, Zichen and Rong, Hao and Li, Mengxia and Xu, Yong and Tian, Long and Qiu, Xiaoming and Liao, Hu and Li, Yalun and Wang, Ke and Tang, Xiaojun and Tian, Panwen and Zhu, Daxing and Zhou, Qinghua and Zhang, Yan},
  title = {Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited‐stage small‐cell lung cancer: A retrospective, multi‐center, real‐world study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {4},
  pages = {1008--1020},
  doi = {10.1002/ijc.70153}
}
Kostenlos starten →